Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
Radionuclide imaging of bone marrow disorders
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-010-1531-0
document
Noninvasive imaging techniques have been used in the past for visualization the functional activity of the bone marrow compartment. Imaging with radiolabelled compounds may allow different bone marrow disorders to be distinguished. These imaging techniques, almost all of which use radionuclide-labelled tracers, such as (99m)Tc-nanocolloid, (99m)Tc-sulphur colloid, (111)In-chloride, and radiolabelled white blood cells, have been used in nuclear medicine for several decades. With these techniques three separate compartments can be recognized including the reticuloendothelial system, the erythroid compartment and the myeloid compartment. Recent developments in research and the...
Effect of radiotherapy and chemotherapy on bone marrow activity: a 18F-FLT-PET study
Published in: Nuclear Medicine Communications
Access to document
10.1097/MNM.0b013e328340798c
Background Radiotherapy (RT) and chemotherapy are important treatment modalities for a variety of malignant tumor types. During therapy for malignant diseases, often the limitation for further therapy is determined by the capability of the bone marrow to withstand radiochemotherapeutic effects. Evaluation of hematologic toxicity is commonly performed with peripheral blood counts, and occasionally, sampling of marrow through a bone marrow biopsy. Neither method provides a comprehensive assessment, as bone marrow biopsy is invasive, and both are subject to sampling variability. Fluorine-18-3′-fluoro-3′-deoxy-L-thymidine-PET (18F-FLT-PET) is a noninvasive method and related...
Ali Agool, Riemer H. J. A. Slart, Kristin K. Thorp, Andor W. J. M. Glaudemans, David C. P. Cobben, Lukas B. Been, Fred R. Burlage, Philip H. Elsinga, Rudi A. J. O. Dierckx, Edo Vellenga, Jennifer L. Holter
The role of radiolabeled anti-TNFα monoclonal antibodies for diagnostic purposes and therapy evaluation
Radiolabelled cytokines and monoclonal antibodies are an emerging class of radiopharmaceuticals for imaging inflammation. These radiopharmaceuticals bind to their targets with high affinity and specificity and therefore have excellent diagnostic potential for imaging of patients with chronic inflammatory diseases. One of the key cytokines involved in the process of inflammation is tumor necrosis factor alpha (TNFα). With the introduction of anti-TNFα monoclonal antibodies over the past decade, treatment of inflammatory diseases has evolved, which allowed remarkable advances in controlling signs and symptoms of inflammation and in slowing destruction....
A. W.J.M. Glaudemans, R. A.J.O. Dierckx, C. G.M. Kallenberg, K. L. Anzola Fuentes
The role of radiolabelled anti-TNF alpha monoclonal antibodies for diagnostic purposes and therapy evaluation
Radiolabelled cytokines and monoclonal antibodies are an emerging class of radiopharmaceuticals for imaging inflammation. These radiopharmaceuticals bind to their targets with high affinity and specificity and therefore have excellent diagnostic potential for imaging of patients with chronic inflammatory diseases. One of the key cytokines involved in the process of inflammation is tumor necrosis factor alpha (TNF alpha). With the introduction of anti-TNF alpha monoclonal antibodies over the past decade, treatment of inflammatory diseases has evolved, which allowed remarkable advances in controlling signs and symptoms of inflammation and in...
A. W. J. M. Glaudemans, R. A. J. Dierckx, C. G. M. Kallenberg, K. L. Anzola Fuentes
Molecular imaging in atherosclerosis
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-010-1406-4
Atherosclerosis is the major cause of cardiovascular disease, which still has the leading position in morbidity and mortality in the Western world. Many risk factors and pathobiological processes are acting together in the development of atherosclerosis. This leads to different remodelling stages (positive and negative) which are both associated with plaque physiology and clinical presentation. The different remodelling stages of atherosclerosis are explained with their clinical relevance. Recent advances in basic science have established that atherosclerosis is not only a lipid storage disease, but that also inflammation has...
Andor W. J. M. Glaudemans, Riemer H. J. A. Slart, Alessandro Bozzao, Elena Bonanno, Marcello Arca, Rudi A. J. O. Dierckx, Alberto Signore